Characterization of CPH:SA microparticle‐based delivery of interleukin‐1 alpha for cancer immunotherapy
Open Access
- 7 December 2022
- journal article
- research article
- Published by Wiley in Bioengineering & Translational Medicine
- Vol. 8 (3) , e10465
Abstract
Background: Interleukin‐1 alpha (IL‐1α) is a pro‐inflammatory cytokine that can activate immune effector cells and trigger anti‐tumor immune responses. However, dose‐limiting toxicities including cytokine storm and hypotension has limited its use in the clinic as a cancer therapy. We propose that polymeric microparticle (MP)‐based delivery of IL‐1α will suppress the acute pro‐inflammatory side effects by allowing for slow and controlled release of IL‐1α systemically, while simultaneously triggering an anti‐tumor immune response.Methods: Polyanhydride copolymers composed of 1,6‐bis‐(p‐carboxyphenoxy)‐hexane:sebacic 20:80 (CPH:SA 20:80) was utilized to fabricate MPs. Recombinant IL‐1α (rIL‐1α) was encapsulated into CPH:SA 20:80 MPs (IL‐1α‐MPs) and the MPs were characterized by size, charge, loading efficiency, and in‐vitro release and activity of IL‐1α. IL‐1α‐MPs were injected intraperitonially into head and neck squamous cell carcinoma (HNSCC)‐bearing C57Bl/6 mice and monitored for changes in weight, tumor growth, circulating cytokines/chemokines, hepatic and kidney enzymes, blood pressure, heart rate, and tumor‐infiltrating immune cells.Results: CPH:SA IL‐1α‐MPs demonstrated sustained release kinetics of IL‐1α (100% protein released over 8–10 days) accompanied by minimal weight loss and systemic inflammation compared to rIL‐1α‐treated mice. Blood pressure measured by radiotelemetry in conscious mice demonstrates that rIL‐1α‐induced hypotension was prevented in IL‐1α‐MP‐treated mice. Liver and kidney enzymes were within normal range for all control and cytokine‐treated mice. Both rIL‐1α and IL‐1α‐MP‐treated mice showed similar delays in tumor growth and similar increases in tumor‐infiltrating CD3+ T cells, macrophages, and dendritic cells.Conclusions: CPH:SA‐based IL‐1α‐MPs generated a slow and sustained systemic release of IL‐1α resulting in reduced weight loss, systemic inflammation, and hypotension accompanied by an adequate anti‐tumor immune response in HNSCC‐tumor bearing mice. Therefore, MPs based on CPH:SA formulations may be promising as delivery vehicles for IL‐1α to achieve safe, effective, and durable antitumor responses for HNSCC patients.Keywords
Funding Information
- National Heart, Lung, and Blood Institute (HL149677)
- National Institute on Aging (AG070188)
- U.S. Department of Veterans Affairs (BX004829)
This publication has 55 references indexed in Scilit:
- A model for cancer-suppressive inflammationOncoImmunology, 2012
- IL-1 acts on T cells to enhance the magnitude of in vivo immune responsesCytokine, 2011
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011
- IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiationProceedings of the National Academy of Sciences, 2009
- Polyanhydrides as localized drug delivery carrier: an updateExpert Opinion on Drug Delivery, 2008
- Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II studyInternational Journal of Gynecological Cancer, 2006
- Activation of Dendritic Cells through the Interleukin 1 Receptor 1 Is Critical for the Induction of Autoimmune MyocarditisJournal of Experimental Medicine, 2003
- IL-1β induces dendritic cells to produce IL-12International Immunology, 2001
- Interleukin 1 Trials in Cancer Patients: A Review of the Toxicity, Antitumor and Hematopoietic EffectsStem Cells, 1996
- Anti‐tumor effects of interleukin‐2 and interleukin‐1 in mice transplanted with different syngeneic tumorsInternational Journal of Cancer, 1989